Literature DB >> 23748915

Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas.

Cláudia Malheiros Coutinho-Camillo1, Silvia Vanessa Lourenço, Suely Nonogaki, José Guilherme Vartanian, Maria Aparecida Nagai, Luiz Paulo Kowalski, Fernando Augusto Soares.   

Abstract

PAR-4 is a tumor suppressor protein with a pro-apoptotic function and down-regulation of PAR-4 is seen in a variety of tumors. PHLDA1 gene overexpression has been shown to reduce cell proliferation and induce cell death in a variety of cell types. In this study, 229 cases of oral squamous cell carcinoma (OSCC), arranged in a tissue microarray, were analyzed by immunohistochemistry. PAR-4 expression was predominantly moderate to strong and expression of PHLDA1 was predominantly negative or weak. Cytoplasmic expression of PAR-4 was associated with advanced clinical stage. Expression of PHLDA1 was associated with advanced clinical stage of the tumour. Five-year overall and disease-free survival rates differed significantly between cases that did and cases that did not express PHLDA1, and by multivariate analysis, expression of PHLDA1 and PAR-4 were independent prognostic factors in OSCC patients. Expression of PAR-4 and PHLDA1 is altered in OSCC and might be a valuable prognostic indicator for this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23748915     DOI: 10.1007/s00428-013-1438-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  34 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Characterization and isolation of stem cell-enriched human hair follicle bulge cells.

Authors:  Manabu Ohyama; Atsushi Terunuma; Christine L Tock; Michael F Radonovich; Cynthia A Pise-Masison; Steven B Hopping; John N Brady; Mark C Udey; Jonathan C Vogel
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

3.  Caspase expression in oral squamous cell carcinoma.

Authors:  Cláudia Malheiros Coutinho-Camillo; Silvia Vanessa Lourenço; Ines Nobuko Nishimoto; Luiz Paulo Kowalski; Fernando Augusto Soares
Journal:  Head Neck       Date:  2010-11-12       Impact factor: 3.147

4.  A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death.

Authors:  C G Park; S Y Lee; G Kandala; S Y Lee; Y Choi
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

5.  Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation.

Authors:  Rüdiger Neef; Martina A Kuske; Elma Pröls; Judith P Johnson
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

6.  PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer.

Authors:  Emmanuel O Johnson; Kuei-Hua Chang; Yolanda de Pablo; Soumitra Ghosh; Rutika Mehta; Sunil Badve; Kavita Shah
Journal:  J Cell Sci       Date:  2011-08-15       Impact factor: 5.285

7.  Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.

Authors:  Gema Moreno-Bueno; Pablo J Fernandez-Marcos; Manuel Collado; Mercedes J Tendero; Socorro M Rodriguez-Pinilla; Isabel Garcia-Cao; David Hardisson; Maria T Diaz-Meco; Jorge Moscat; Manuel Serrano; Jose Palacios
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

8.  Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma.

Authors:  Cláudia Malheiros Coutinho-Camillo; Silvia Vanessa Lourenço; Ines Nobuko Nishimoto; Luiz Paulo Kowalski; Fernando Augusto Soares
Journal:  Histopathology       Date:  2010-08       Impact factor: 5.087

9.  TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the cevelopment of atherosclerosis in hyperhomocysteinemia.

Authors:  Gazi S Hossain; Johannes V van Thienen; Geoff H Werstuck; Ji Zhou; Sudesh K Sood; Jeffrey G Dickhout; A B Lawrence de Koning; Damu Tang; Dongcheng Wu; Erling Falk; Ranjana Poddar; Donald W Jacobsen; Kezhong Zhang; Randal J Kaufman; Richard C Austin
Journal:  J Biol Chem       Date:  2003-05-08       Impact factor: 5.157

10.  TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.

Authors:  Michael D Oberst; Stacey J Beberman; Liu Zhao; Juan Juan Yin; Yvona Ward; Kathleen Kelly
Journal:  BMC Cancer       Date:  2008-07-02       Impact factor: 4.430

View more
  9 in total

1.  Differentially Expressed Long Non-Coding RNAs Were Predicted to Be Involved in the Control of Signaling Pathways in Pediatric Astrocytoma.

Authors:  Ruth Ruiz Esparza-Garrido; Juan Manuel Rodríguez-Corona; Javier Enrique López-Aguilar; Marco Antonio Rodríguez-Florido; Ana Claudia Velázquez-Wong; Rubí Viedma-Rodríguez; Fabio Salamanca-Gómez; Miguel Ángel Velázquez-Flores
Journal:  Mol Neurobiol       Date:  2016-10-13       Impact factor: 5.590

2.  Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma.

Authors:  P O Zhao; Xiaoying Li; Yali Lu; Lin Liu
Journal:  Oncol Lett       Date:  2015-06-03       Impact factor: 2.967

3.  The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.

Authors:  Yinxing Liu; Misty R Gilbert; Natasha Kyprianou; Vivek M Rangnekar; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2014-08-19       Impact factor: 17.088

4.  PHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras.

Authors:  Jiutao Wang; Ning Yao; Yamei Hu; Mingjuan Lei; Meixian Wang; Lu Yang; Satyananda Patel; Xiang Li; Kangdong Liu; Zigang Dong
Journal:  Cell Mol Life Sci       Date:  2022-09-15       Impact factor: 9.207

5.  Pleckstrin homology-like domain, family A, member 1 (PHLDA1) and cancer.

Authors:  Maria Aparecida Nagai
Journal:  Biomed Rep       Date:  2016-01-25

6.  Circ_0027599/PHDLA1 suppresses gastric cancer progression by sponging miR-101-3p.1.

Authors:  Liang Wang; Jingyan Shen; Yushan Jiang
Journal:  Cell Biosci       Date:  2018-11-06       Impact factor: 7.133

7.  Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T-lymphocytes: A bioinformatic analysis.

Authors:  Runzhi Huang; Dan Huang; Siqiao Wang; Shuyuan Xian; Yifan Liu; Minghao Jin; Xinkun Zhang; Shaofeng Chen; Xi Yue; Wei Zhang; Jianyu Lu; Huizhen Liu; Zongqiang Huang; Hao Zhang; Huabin Yin
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

8.  PHLDA1, another PHLDA family protein that inhibits Akt.

Authors:  Yu Chen; Masahiro Takikawa; Shuichi Tsutsumi; Yoko Yamaguchi; Atsushi Okabe; Mayuna Shimada; Tatsuya Kawase; Akane Sada; Issei Ezawa; Yuhei Takano; Kisaburo Nagata; Yutaka Suzuki; Kentaro Semba; Hiroyuki Aburatani; Rieko Ohki
Journal:  Cancer Sci       Date:  2018-10-13       Impact factor: 6.716

9.  PHLDA1 expression in ulcerative colitis: A potential role in the management of dysplasia.

Authors:  Fukuichiro Orita; Toshiaki Ishikawa; Megumi Ishiguro; Satoshi Okazaki; Akifumi Kikuchi; Shinichi Yamauchi; Takatoshi Matsuyama; Masanori Tokunaga; Hiroyuki Uetake; Yusuke Kinugasa
Journal:  Mol Clin Oncol       Date:  2021-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.